



PHOTONICS PUBLIC PRIVATE PARTNERSHIP

PHOTONICS<sup>21</sup>



*H2020-ICT-2019-2*

*Photonics Manufacturing Pilot Lines for Photonic Components and Devices*

## **MedPhab**

**Photonics Solutions at Pilot Scale for Accelerated Medical Device Development**

Starting date of the project: 01/01/2020

Duration: 48 months

**= Open calls for demo cases =  
Evaluation  
ONLY FOR EVALUATORS**



*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 871345.*

## MedPhab Evaluation guidelines

MedPhab, the first European pilot line for photonics-based medical devices funded under Horizon 2020, organises an open Call for Demo Cases for the external companies developing medical products to validate MedPhab's open access business model and services. The objective of the Open Call is to provide technology development services for the companies that are adopting advanced photonics technologies in the medical diagnostics solutions. As the technology development services are pioneering in nature, MedPhab provides subsidized financial support to up to 20 business cases (an average of 6 cases per cut-off).

### Evaluation team

MedPhab full proposal evaluation team is conformed by the following people:

| No. | Partner | Name of Evaluator  |
|-----|---------|--------------------|
| 1   | VTT     | Jussi Hiltunen     |
| 2   | VTT     | Ralph Liedert      |
| 3   | IMEC    | Roel Baets         |
| 4   | IMEC    | Kamalpreet Kaur    |
| 5   | PINS    | Sieger Swaving     |
| 6   | PINS    | Willem-Jan de Wijs |
| 7   | CSEM    | Nenad Marjanovic   |
| 8   | CSEM    | Felix Kurth        |
| 9   | JOR     | Jan Hesse          |
| 10  | JOR     | Martin Smolka      |
| 11  | TNI     | Ray Burke          |
| 12  | TNI     | David Mc Govern    |

The proposal will be evaluated following three main criteria as described below. Experts score each award criterion on a scale from 0 to 5 (half point scores may be given):

0 – Proposal fails to address the criterion or cannot be assessed due to missing or incomplete information.

1 – Poor. The criterion is inadequately addressed or there are serious inherent weaknesses.

2 – Fair. The proposal broadly addresses the criterion, but there are significant weaknesses.

3 – Good. The proposal addresses the criterion well, but a few shortcomings are present.

4 – Very good. The proposal addresses the criterion very well, but a small number of shortcomings are present.

5 – Excellent. The proposal successfully addresses all relevant aspects of the criterion. Any shortcomings are minor.

The threshold for individual criteria is 3 (out of 5) and the overall threshold is 10 (out of 15). In order to be considered for support, the proposal must score above both the average of individual criteria and overall thresholds. If a same score is found between two proposals, a weighted system will used for ranking them: Impact 0.5, Concept 0.4 and Implementation 0.1. An example in the next table for this system in which Proposal IV do not go through because of an under-threshold score in implementation even though the other section had perfect score.

|                 | Weight | Proposal I | Proposal II | Proposal III | Proposal IV |
|-----------------|--------|------------|-------------|--------------|-------------|
| Impact          | 0.5    | 3          | 4           | 5            | 5           |
| Concept         | 0.4    | 4          | 4           | 4            | 5           |
| Implementation  | 0.1    | 5          | 4           | 3            | 2           |
| Weighted points |        | 3.6        | 4           | 4.4          | 4.7         |

## 1. Evaluation Form

### 1.1. General questions

*This section will not be scored, but comments could be provided.*

- Is the applicant SME or large enterprise?
- Which MedPhab technologies are relevant?
- How the case/proposal will be used in medical device development?
- What is the planned application field? (hospital environment, in vitro/in vivo diagnostics, therapeutics, other)?
- Which MedPhab partner helped in the preparation of the proposal ?

### 1.2. Proposal sections

All sections below will be scored and commented. Make sure that comments reflect the assigned marks/scores.

#### 1.2.1. Concept

*This section should cover and be scored on the following criteria: the objective of the Demo-Case and technological challenges to overcome. The objective should be clear, measurable and achievable within the duration and resources of the project. Describe the target for technology readiness levels (TRL) and if applicable also for manufacturing readiness level (MRL). Please reply also to questions: How do MedPhab services help to solve the challenge described? Which regulatory requirements are needed during and/or after the implementation of the Demo-Case? Is there a need for Quality Management Systems? Are there any potential ethical issues?*

Has the applicant addressed and clearly demonstrated the following key points:

#### **Alignment with the call**

- The Demo-Case demonstrates that MedPhab's photonics technology offerings give a distinct advantage to the concept/case/product value in a medical application
- That a clear majority of the objectives and activities are focusing on one or more MedPhab capabilities (modularity table) comprising:
  - *Photonic component*
  - *Non-photonic peripherals*
  - *Integration*
  - *Post-processing*
  - *Development support*
- That the Case leads to an innovative product demonstrator
- In a case of manufacturing/upscaling support :
  - That a clear majority of the objectives and activities are focusing on transforming the existing demonstrator into a small series of demonstrators
  - That manufacturing technologies will be applied for their uniqueness enabling state-of-the-art performance.

#### **Needs and challenges**

- Business Need
  - The Demo-Case supports to meet the business needs of the Product
  - The Demo-Case will lead to improved performance compared to currently available products in the market, or this Product will open new markets
- Technological challenge

### MedPhab

- Work already carried out to address this need. For example, is the Demo-Case focused on maturing an existing capability or developing a new one ?
- Are results from previous work included in the Demo-Case?
- Described the nearest current state-of-the-art (including those near-market / in development) and its limitations

#### 1.2.2. Implementation

*This section should cover and be scored on the following criteria: a draft outline of work activities, timeline, deliverables, milestones, the team involved, any risks identified and their mitigation strategy, IP agreement between the involved parties and budget and planning of resources to be committed for the demo-case.*

Has the applicant addressed and clearly demonstrated the following key points:

- **Project implementation**
  - *Proposed activities within the demo-case highlighting key inputs and deliverables*
  - *What “in-kind services” Innovative Company will bring in order to deliver the Demo-case*
  - *Outlined budget on how the Demo-case budget contribution, and third party contribution will be spent.*
- **Company description**
  - *What resources, equipment and processes the company has access to in relation to delivery of this case*
  - *Described the existing supply chain and how this will be engaged*
- **Team**
  - *Explained the roles, skills and relevant experience of the team in relation to the approach to be taken, including any previous project management experience and provided mini CV’s*
  - *Outlined the management reporting lines (for example an organogram)*
- **Risks and mitigations**
  - *Key risks and uncertainties of the Demo-case, including any technical, commercial, managerial and environmental risks*
  - *Provided risk register and how these risks will be mitigated*
  - *Demo-case inputs required on the critical path to completion (for example; any resources, expertise, data sets, etc.)*

#### 1.2.3. Impact

*This section should cover and be scored on the following criteria: How successful completion of the Demo Case accelerates the product launch or incorporating new feature in a product? What is the expected business growth and/or productivity increase into the long term as a result of the Demo Case? Optional, other expected impacts, such as, societal, environmental, and economic impacts outside the company/organisation.*

Has the Company addressed and clearly demonstrated the outcomes and how they will grow their businesses into the long term as a result of the Demo-case? This should include:

- **Outcomes**

- *Outputs expected from the Demo-case (for example, what will the Product Demonstrator / series of products show, is there any know-how, new process, product or service design) and how these will take the Company closer to addressing the need, challenge or opportunity identified*
- *Current position in the market(s) and supply / value chains outlined (will they be extending or establishing your market position?)*
- *Target customers and / or end users, and the value proposition to them (why would they use / buy it?)*
- *How photonics will impact the company productivity, growth and competitiveness (in the short and long-term) ?*

- **Wider Impact**

- *What impacts the Demo-case have outside the project team*
- *identified, and where possible quantified, the economic benefits from the Demo-case to external bodies (for example, customers, others in the supply chain, broader industry and the EU economy) such as productivity increases and import substitution*
- *Identified and where possible quantified, any expected environmental impacts, either positive or negative*
- *Are any trans-national impacts of the Demo-case (for example; is there any other country involved in the supply chain, is one of your subcontractors from another country)*
- *Indicated if the Product Demonstrator will be cross-cutting across multiple industry sectors or markets*

- **Strategy**

- *Provided a total budget for the business case including: marketing; first trials; sales channel and technical product development and manufacturing scale-up investment*
- *Any milestones that have been set for the development and market entry*
- *The value chain(s) for the Product Demonstrator to be turned into a Commercial Product. (Any gaps in the value chain to be highlighted)*
- *Indicated access to any potential Investors, has the Innovative Company already engaged in any discussions with Venture Capitalists*

### 1.3. Others

**Further remarks:**

*This can include any other comment / remark in general related to any information / answer provided by the applicant. This will not be scored.*

## 2. Confidentiality clause

Even though an NDA will be signed by organizations with a representative in the ET, a confidentiality clause is included in the evaluation software which states:

*I undertake to treat all information contained in the proposal which I am asked to evaluate as confidential both during and following the evaluation.*

MedPhab

*I declare that, to the best of my knowledge, I have no direct or indirect conflict of interest with the proposal.*

*I do not, to the best of my knowledge, have any interest in any of the proposals submitted in this call, I have not been involved in their preparation and I do not benefit either directly or indirectly from the eventual selection.*

*Should I discover a conflict of interest during the evaluation, I undertake to declare this and to withdraw from the evaluation.*

*I will not reveal to any third party the identity or any details of the views of my fellow evaluator(s), neither during the evaluation nor afterwards.*